Date: August 13, 2025
Companies: BioCardia, Inc. (Nasdaq: BCDA)& CART-Tech B.V.
Subject: Exclusive Partnership– Heart3D™ Fusion Imaging
BioCardia and CART-Tech have formed an exclusive partnership to develop and commercialize Heart3D™ Fusion Imaging, a system that merges 3D heart models from MRI/CT with real-time 2D X-ray images to guide cardiac biotherapeutic delivery and biopsy procedures. Initially, it will be sold as a research tool for preclinical studies, with plans for later regulatory approval for clinical use. BioCardia gains exclusive worldwide rights for biotherapeutic delivery and U.S. rights for cardiac biopsy, while CART-Tech retains other rights. The technology aims to improve procedural planning, image precision, and patient outcomes, with a potential $100M annual revenue opportunity if adopted as a standard of care. Currently, the system is for investigational use only and not yet CE-marked or FDA approved.
オランダCART-Techとの大型契約発表あり🍵
ここの基盤技術Heart3D Fusion Imagingを使うと、MRIやCTで事前に作った患者の3D心臓モデルを手術中のX線映像にリアルタイムで重ね合わせできる心臓カテーテル治療用GPS。
最大のメリットは、特定メーカーの医療装置に縛られず、今ある設備に“後から追加”して使える柔軟性。
Heart3Dは現状では動物試験などの研究用ツールですが、最短でも3年、現実的には4〜5年のプロセスを経て、細胞治療の臨床試験や商業利用に組み込める可能性が高い。
Date: August 13, 2025
Companies: BioCardia, Inc. (Nasdaq: BCDA)& CART-Tech B.V.
Subject: Exclusive Partnership– Heart3D™ Fusion Imaging
BioCardia and CART-Tech have formed an exclusive partnership to develop and commercialize Heart3D™ Fusion Imaging, a system that merges 3D heart models from MRI/CT with real-time 2D X-ray images to guide cardiac biotherapeutic delivery and biopsy procedures. Initially, it will be sold as a research tool for preclinical studies, with plans for later regulatory approval for clinical use. BioCardia gains exclusive worldwide rights for biotherapeutic delivery and U.S. rights for cardiac biopsy, while CART-Tech retains other rights. The technology aims to improve procedural planning, image precision, and patient outcomes, with a potential $100M annual revenue opportunity if adopted as a standard of care. Currently, the system is for investigational use only and not yet CE-marked or FDA approved.
投資の参考になりましたか？